| 2023-01-19 |
详情>>
内部人交易：
BAILEY MICHAEL P等共交易4笔
|
| 2022-11-25 |
股东大会：
将于2023-01-05召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the “Merger Agreement”), dated as of October 18, 2022, among LG Chem, Ltd., a corporation organized and existing under the laws of the Republic of Korea (referred to as “LG Chem”), Acacia Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of LG Chem (referred to as “Merger Sub”), and AVEO, pursuant to which Merger Sub will be merged with and into AVEO, with AVEO surviving the merger as an indirect wholly owned subsidiary of LG Chem (referred to as the “Merger”);
2.To consider and vote on a proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to AVEO’s named executive officers that is based on or otherwise relates to the Merger;
3.To consider and vote on a proposal to approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to approve the proposal to adopt the Merger Agreement at the time of the special meeting (the special meeting and any adjournments or postponements thereof, referred to as the “Special Meeting”).
|
| 2022-11-07 |
详情>>
股本变动：
变动后总股本3476.31万股
|
| 2022-11-07 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.63美元,归母净利润-2178.4万美元,同比去年增长52.73%
|
| 2022-08-04 |
详情>>
业绩披露：
2022年中报每股收益-0.54美元,归母净利润-1851.8万美元,同比去年增长48.16%
|
| 2022-08-04 |
财报披露：
美东时间 2022-08-04 盘前发布财报
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.3美元,归母净利润-1019.9万美元,同比去年增长53.90%
|
| 2022-04-26 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.Elect seven directors, each to serve for a one-year term expiring at our 2023 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.
2.Approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 50,000,000 to 80,000,000.
3.Approve an amendment to the AVEO Pharmaceuticals, Inc. 2019 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.
4.Approve an amendment to the AVEO Pharmaceuticals, Inc. Amended and Restated 2010 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance thereunder from 576,400 to 876,400.
5.Approve an advisory vote on executive compensation.
6.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022.
|
| 2022-03-14 |
详情>>
业绩披露：
2019年年报每股收益0.61美元,归母净利润938.80万美元,同比去年增长276.17%
|
| 2022-03-14 |
详情>>
业绩披露：
2021年年报每股收益-1.63美元,归母净利润-5334.2万美元,同比去年增长-49.9%
|
| 2021-11-08 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.44美元,归母净利润-4608.7万美元,同比去年增长-91.39%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2020年中报每股收益-0.94美元,归母净利润-1568.7万美元,同比去年增长-508.02%
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-1.16美元,归母净利润-3571.9万美元,同比去年增长-127.7%
|
| 2021-05-10 |
详情>>
业绩披露：
2021年一季报每股收益-0.81美元,归母净利润-2212.2万美元,同比去年增长-163.95%
|
| 2021-04-28 |
股东大会：
将于2021-06-09召开股东大会
会议内容 ▼▲
- 1.Elect seven directors, each to serve for a one-year term expiring at our 2022 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.
2.Approve an amendment to the AVEO Pharmaceuticals, Inc. 2019 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.
3.Approve the amendment and restatement of the 2010 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance thereunder from 76,400 to 576,400 and to make certain other changes.
4.Approve an advisory vote on executive compensation.
5.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.
|
| 2021-03-16 |
详情>>
业绩披露：
2020年年报每股收益-1.66美元,归母净利润-3558.4万美元,同比去年增长-479.04%
|
| 2021-03-11 |
复牌提示：
2021-03-10 15:07:37 停牌，复牌日期 2021-03-10 15:12:37
|
| 2020-11-09 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-1.22美元,归母净利润-2408万美元,同比去年增长-273.88%
|
| 2020-04-28 |
股东大会：
将于2020-06-10召开股东大会
会议内容 ▼▲
- 1.To elect six directors, each to serve for a one-year term expiring at the 2021 annual meeting of stockholders;
2.To approve an advisory vote on executive compensation;
3.To approve an amendment to the AVEO Pharmaceuticals, Inc. 2019 Equity Incentive Plan to increase the number of shares available for issuance under the plan and to make certain other changes;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020.
|
| 2020-02-20 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2020-01-08 |
股东大会：
将于2020-02-13召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our common stock, by a ratio of not less than 1-for-5 and not more than 1-for-15, and a proportionate reduction in the number of authorized shares of common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of our board of directors, or the Reverse Stock Split Proposal.
|
| 2019-04-30 |
股东大会：
将于2019-06-12召开股东大会
会议内容 ▼▲
- 1.To elect five directors, each to serve for a one-year term expiring at the 2020 annual meeting of stockholders;
2.To approve an advisory vote on executive compensation;
3.To approve the AVEO Pharmaceuticals, Inc. 2019 Equity Incentive Plan;
4.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 250,000,000 to 500,000,000;
5.To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our common stock, by a ratio of not less than 1-for-5 and not more than 1-for-15, and a proportionate reduction in the number of authorized shares of common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of our board of directors;
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019.
|
| 2018-04-27 |
股东大会：
将于2018-06-18召开股东大会
会议内容 ▼▲
- 1.To elect five directors, each to serve for a one-year term expiring at the 2019 annual meeting of stockholders;
2.To approve an advisory vote on executive compensation;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018.
|
| 2017-04-27 |
股东大会：
将于2017-06-21召开股东大会
会议内容 ▼▲
- 1.To elect five directors, each to serve for a one-year term expiring at the 2018 annual meeting of stockholders;
2.To approve an advisory vote on executive compensation;
3.To hold an advisory vote on the frequency of future executive compensation advisory votes;
4.To approve a Second Amended and Restated 2010 Stock Incentive Plan to reserve up to an additional 3,500,000 shares of common stock for issuance under the plan and to provide for certain other amendments;
5.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 200,000,000 to 250,000,000;
6.To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our common stock, by a ratio of not less than 1-for-3 and not more than 1-for-15, such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of our board of directors;
7.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2017.
|
| 2016-04-14 |
股东大会：
将于2016-05-26召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for a one-year term expiring at the 2017 annual meeting of stockholders;
2.To approve an advisory vote on executive compensation;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2016.
|
| 2015-04-17 |
股东大会：
将于2015-05-28召开股东大会
会议内容 ▼▲
- 1. To elect seven directors to serve for a one-year term expiring at the 2016 annual meeting of stockholders;
2. To approve an amendment to our restated certificate of incorporation to increase the number of authorized shares of our common stock from 100,000,000 shares to 200,000,000 shares;
3. To approve an advisory vote on executive compensation;
4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2015.
|
| 2014-04-30 |
股东大会：
将于2014-06-19召开股东大会
会议内容 ▼▲
- 1. To elect six directors to serve for a one-year term expiring at the 2015 annual meeting of stockholders;
2. To amend our Amended and Restated 2010 Stock Incentive Plan to increase the annual per participant share limit from 250,000 to 1,000,000 shares;
3. To approve an advisory vote on executive compensation;
4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2014.
|
| 2013-04-26 |
股东大会：
将于2013-05-29召开股东大会
会议内容 ▼▲
- 1. To elect eight directors to serve for a one-year term expiring at the 2014 annual meeting of stockholders;
2. To amend and restate our 2010 Stock Incentive Plan to reserve up to an additional 3,000,000 shares of common stock for issuance under the 2010 Stock Incentive Plan and to provide for certain other amendments;
3. To amend our 2010 Employee Stock Purchase Plan to reserve up to an additional 514,000 shares of common stock for issuance under the 2010 Employee Stock Purchase Plan;
4. To approve an advisory vote on executive compensation;
5. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2013.
|